haemonetics corp/mass (HAE) Key Developments
Haemonetics Corporation Unveils New HaemoCloud IoT Software Platform
Aug 26 15
Haemonetics Corporation has unveiled HaemoCloud, a new internet of things, or IoT, software platform designed to connect all Haemonetics devices and software. HaemoCloud is a foundational suite of products including HaemoCommunicator and HaemoCloud, which allow Haemonetics blood management devices to communicate with hospital information systems and provide real-time device operational data for service and support. This strategy embraces the Internet of Things to create smart, safe, connected products that will improve the level of care and drive down costs across the entire blood value chain. HaemoCommunicator works within an institution to format and transfer data from diagnostic thromboelastography (i.e., TEG 6s) and cell salvage devices (i.e., Cell Saver Elite). Operational data from the device is also managed by HaemoCommunicator to provide lab and IT staff real-time access to device performance. On a nightly basis, each HaemoCommunicator installation compiles device performance data and transfers it to HaemoCloud allowing Haemonetics' customers and support organizations to monitor the use and performance of each device. HaemoCommunicator is designed to integrate with both Haemonetics and competitive devices, to create a seamless data experience for customers.
Haemonetics Corporation Presents at 8th Annual Barrington Research Fall Conference 2015, Sep-02-2015
Aug 20 15
Haemonetics Corporation Presents at 8th Annual Barrington Research Fall Conference 2015, Sep-02-2015 . Venue: Four Seasons Hotel Chicago, 900 North Michigan Shops, 120 E Delaware Place, Chicago, IL 60611, United States.
Haemonetics Corporation Announces Executive Changes
Jul 30 15
On July 29, 2015 Peter Allen resigned as President, Global Plasma at Haemonetics Corporation to pursue other opportunities. Thomas McCurdy, who has served as Vice President, North America Patient Sales since 2010, has been appointed as Mr. Allen's successor, effective immediately.
Haemonetics Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 27, 2015; Reaffirms Earnings Guidance for the Fiscal Year 2016
Jul 27 15
Haemonetics reported unaudited consolidated earnings results for the first quarter ended June 27, 2015. For the quarter, the company reported net revenues of $213.413 million against $224.488 million a year ago. Operating income was $3.606 operating loss of $1.666 million a year ago. Income before taxes was $1.597 million against loss before taxes of $4.209 million a year ago. Net loss was $0.267 million against $3.649 million a year ago. Net loss per common share assuming dilution was $0.01 million against $0.07 million a year ago. Net cash provided by operating activities was $9.250 million against $13.738 million a year ago. Capital expenditures on property, plant and equipment was $24.246 million against $37.085 million a year ago. Non-GAAP operating income was $25.827 million against $28.778 million a year ago. Non-GAAP income before taxes was $23.818 million against $26.458 million a year ago. Non-GAAP net income was $17.984 million against $19.725 million a year ago. Non-GAAP net income per common share assuming dilution was $0.35 against $0.38 a year ago. The Company reported free cash flow, before transformation and restructuring costs, of $1 million in the first quarters of fiscal 2016 and 2015.
The company reaffirmed its previous fiscal 2016 guidance for revenue growth of 4-6%, implying a range of $946.5 million to $965 million. The company continues to expect approximately 46% of revenue in the first half and 54% in the second half of the fiscal year. The company reaffirmed full year adjusted earnings per share in the range of $1.98 to $2.08, representing 7% to 12% earnings growth over fiscal 2015. The company continues to expect approximately 35% of fiscal 2016 earnings to be realized in the first half of the year and 65% in the second half. Free cash flow guidance for fiscal 2016 is reaffirmed in the range of $105 million to $110 million before funding approximately $27 million of capital expenditures and cash transformation expenditures to complete the VCC initiatives. Acquisition related amortization is expected to approximate $30 million, or $0.40 per share, and is excluded from adjusted operating income and adjusted earnings per share. Full year guidance is for adjusted gross margin to average between 48% and 49%, adversely affected by mix and currency and positively affected by VCC and other structural cost improvements. Adjusted operating margin is expected to average between 15% to 16%. In constant currency, the company is reaffirming the company fiscal 2016 earnings growth rate of 15% to 20%.
Haemonetics Corporation Presents at UBS SMID Cap One-on-One Conference, Aug-04-2015
Jul 18 15
Haemonetics Corporation Presents at UBS SMID Cap One-on-One Conference, Aug-04-2015 . Venue: Boston Harbor Hotel, 70 Rowes Wharf, Boston, MA 02110, United States. Speakers: Christopher J. Lindop, Chief Financial Officer and Executive Vice President of Business Development, Gerard J. Gould, Vice President of Investor Relations, Peter M. Allen, President of Global Plasma.